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Associations between LSAMP gene polymorphisms
and major depressive disorder and panic disorder
K Koido1,2, T Traks1,2, R Balõtšev3, T Eller3, A Must1,2, S Koks1,2, E Maron3,4, I Tõru3, J Shlik5, V Vasar3 and E Vasar1,2
The purpose of this case–control genetic association study was to explore potential relationships between polymorphisms in the
limbic system-associated membrane protein (LSAMP) gene and mood and anxiety disorders. A total of 21 single-nucleotide
polymorphisms (SNPs) from the LSAMP gene were analyzed in 591 unrelated patients with the diagnoses of major depressive
disorder (MDD) or panic disorder (PD) and in 384 healthy control subjects. The results showed a strong association between
LSAMP SNPs and MDD, and a suggestive association between LSAMP SNPs and PD. This is the first evidence of a possible role
of LSAMP gene in mood and anxiety disorders in humans.
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Introduction
Major depressive disorder (MDD) and panic disorder (PD) are
prevalent and serious psychiatric disorders commonly
manifesting in young adult age and affecting females more
often than males.1,2 The data from twin and family studies
suggest a substantial involvement of genetic factors in the
familial transmission of MDD and PD, with heritability
estimates for MDD in the range of 31 42%,3 or as high
as 70%,4 and for PD near 40%.5 It has been established
that MDD and PD are highly comorbid and that shared
genetic risk factors largely account for their comorbidity.6
However, the specific genes or their variants responsible
for heritability or expression of these disorders remain
undetermined.
The limbic system-associated membrane protein (LSAMP)
is a 64- to 68-kDa glycoprotein that is found on the somata and
dendrites of neurons of cortical and subcortical regions
comprising the adult mammalian limbic system, which is
involved in the mediation of emotional behavior, learning,
memory and central autonomic regulation.7,8 LSAMP is a
member of immunoglobulin superfamily, with three immuno-
globulin domains and a glycosyl–phosphatidylinositol
anchor.9 It has been suggested that LSAMP acts as a
necessary molecular component for the formation of proper
connections between the limbic system regions.7 In humans,
the LSAMP gene is located in the 3q13.2-q21 chromosomal
region, which consists 7 exons and shows 94% identity at the
nucleotide level, and 99% sequence identity at the encoded
338-amino-acid polypeptides level with rat LSAMP cDNA.10
Human studies have shown that LSAMP may have a role in
the neurobiology of suicidal behavior.11 Proteomic assess-
ment has strongly implicated LSAMP in schizophrenia and
bipolar disorder,12 demonstrating its increased level in the
dorsolateral prefrontal cortex. Furthermore, stronger or weaker
linkages have been shown in the long arm of chromosome
3 with recurrent early-onset MDD or anxiety,13 agoraphobia,14
schizophrenia,15–18 bipolar disorder19,20 and autism-
spectrum disorders.21 A number of genome-wide association
studies of depression have mainly given results that did
not meet a genome-wide threshold for significance, but there
were associations between depression and LSAMP or
adjacent gene loci in top findings of all publications.22–29
In animal studies, it has been shown that the anxious rats
display 1.6-fold higher expression of Lsamp gene compared
to the non-anxious rats in the periaqueductal gray.30 Similar
results have been reported for the amygdala, demonstrating
that the anxious rats display 2.4-fold higher expression of the
Lsamp gene compared with the non-anxious rats.31 Upregu-
lated Lsamp expression was also detected in the raphe, the
hippocampus and the frontal cortex of the highly anxious
rats.32 The studies in Lsamp-deficient mice demonstrated the
reduced anxiety and increased sensitivity to anxiolytic action
of diazepam in these animals.33 The findings above suggest
the importance of LSAMP in emotional regulation and make
the LSAMP gene a good candidate for genetic research on
mood and anxiety disorders. The purpose of the present study
was to detect associations of genetic polymorphisms in the
LSAMP gene with MDD and PD.
Materials and methods
Subjects and psychiatric assessment. Unrelated patients
with the diagnoses of MDD or PD (n¼ 591) were enrolled in
the study along with healthy control individuals (n¼ 384). The
patients were recruited from consecutive outpatients and
inpatients at the Clinic of Psychiatry of the Tartu University
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Hospital, and healthy subjects were recruited by newspaper
advertisement in Tartu, Estonia. The diagnostic status of the
patients was substantiated by a psychiatric interview and
verified by the Mini International Neuropsychiatric Interview
(MINI 5.0.0) based on DSM-IV criteria.34 Controls were
evaluated by the MINI and family history interview, to exclude
those with psychiatric morbidity and a history of major
psychiatric disorders in first-degree relatives. All subjects
were of white European ancestry and living in Estonia. The
patients were divided into MDD (n¼ 395) and PD (n¼ 196)
subgroups according to the primary diagnosis. MDD or PD
was considered primary if it was the principal diagnosis at the
time of the investigation and/or had an earlier onset in the
course of illness. Patients in MDD group were either pure
MDD or MDD comorbid with anxiety disorders. Patients in PD
group were either pure PD, or comorbid with mood or other
anxiety disorders. The control group was the same for MDD
and PD, with an exception of reducing the number of male
subjects in control group for PD to reflect the respective
male/female ratio in the PD group. There were no significant
differences in age or sex between the patients and healthy
controls (w2 and P-value for gender of MDD and PD groups
are 2.74 and P¼ 0.098, and 3.35 and P¼ 0.067, respec-
tively). Demographic characteristics of the study subjects are
presented in Table 1. The study protocol was approved by
the Ethics Review Committee on Human Research of the
University of Tartu. Each subject provided a written informed
consent before participation.
SNP selection, DNA preparation and genotyping. Tag
single-nucleotide polymorphisms (SNPs) were selected
from the LSAMP gene and flanking regions (150 kb fragment
from 116931222–117081732; and 242 kb fragment from
117428563–117670401) using the Tagger algorithm (r2¼ 0.8,
minor allele frequency 40.05) implemented in Haploview
3.32.11 Standard high-salt extraction method was used to
isolate genomic DNA from 9ml venous blood samples. SNP
detection was performed by SNPlex Genotyping System
(Applied Biosystems, Foster City, CA, USA). This system is
based on the oligonucleotide ligation/PCR assay with a
universal ZipChute (Applied Biosystems) probe detection
for high throughput SNP genotyping. Fluorescent-labeled
ZipChute probes are hybridized to complementary ZipCode
(Applied Biosystems) sequences that are part of genotype-
specific amplicons. These ZipChute probes are eluted and
detected by electrophoretic separation on Applied Biosys-
tems 3730 DNA Analyzers. The system analysis software
collects and manages raw data and provides automated
allele calling and quality metrics.35
Statistical analysis. Genotypes were determined by Gene-
Mapper 3.7 (Applied Biosystems). Allelic association, linkage
disequilibrium and haplotype analyses between groups of
patients and controls, and Hardy–Weinberg equilibrium calcula-
tions in the control group were performed using Haploview
Version 4.0 software.36 The significance level for all statistical
tests was 0.05. The algorithm for defining haplotype blocks
was an internally developed method Solid Spine of linkage
disequilibrium (D040.75). Ten thousand permutations were
used to correct P-values for multiple testing. Closer analysis of
haplotype block nr 5 was performed with Statistica software
(Information Technology Office, University of Tartu, Tartu,
Estonia).
Results
We genotyped a total of 22 SNPs from the LSAMP gene in
591 unrelated psychiatric patients and 384 healthy controls.
One SNP (rs4831129) was excluded from the further analysis
because of a bias from Hardy–Weinberg equilibrium in the
control group (P-value cut-off 0.01).
Allelic association analysis. The results of allelic associa-
tion analysis of 21 SNPs are presented in Table 2. Four SNPs
showed significant associations in MDD group—rs16824691,
rs1461131, rs4831089 and rs9874470 (P-values 0.004,
o0.001, o0.001 and o0.001, respectively). For the last three
of these SNPs, the P-values remained statistically significant
after 10 000 permutations (odds ratios, 95% confidence inter-
vals and permutation P-values 1.43, 1.17–1.76 and 0.0228;
1.53, 1.24–1.89 and 0.0015; and 0.63, 0.5–0.78 and 0.0005,
respectively). Two SNPs showed significant associations in
PD group—rs1461131 and rs4831089 (P-values 0.033 and
0.018, respectively). These P-values did not remain statis-
tically significant after correction for multiple testing.
A separate analysis of allelic association by gender
revealed significant associations with the same four SNPs
as whole-group analysis. The SNPs rs1461131, rs4831089
and rs9874470 (P-values 0.005, 0.005 and 0.007, respec-
tively) differed significantly between females of the MDD
group and their respective controls. No significant association
was detected in the female PD group. The SNPs rs1682469,
rs4831089 and rs9874470 (P-values 0.01, 0.004 ando0.001,
respectively) differed significantly between males of the MDD
group and their controls. The SNPs rs1461131, rs4831089
and rs9874470 (P-values 0.003, 0.005 and 0.03, respectively)
differed significantly between males of PD group and their
controls. These P-values did not remain statistically signifi-
cant after correction for multiple testing, except rs9874470 in
the maleMDD group (odds ratio (95% confidence intervals)¼
0.49 (0.33–0.73); permutation P¼ 0.01).
Haplotype analysis. Haplotype analysis revealed seven
haplotype blocks in both patient groups (see Figure 1 for
haplotype blocks in MDD group). Haplotypes of block nr 5
(rs9874470, rs4831089, rs16824691 and rs1461131) in MDD
and PD groups differed statistically significantly between
patient groups and healthy control groups (Tables 3 and 4).
Haplotype TATA was a risk haplotype in MDD group
(Po0.001) and in PD group (P¼ 0.020). P-value remained









N 395 384 196 364
Sex (male/female) 114/281 132/252 46/150 112/252
Age (years),
mean±s.d.
37.0±13.8 37.6±13.6 38.1±12.7 37.8±13.6
Range (years) 17–73 16–71 18–73 16–71
Abbreviations: MDD, major depressive disorder; PD, panic disorder.
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statistically significant after 10 000 permutations in MDD group
(odds ratio (95% confidence intervals)¼ 1.55 (1.26–1.91);
permutation P¼ 0.0008), but did not survive the correction in
the PD group. Two haplotypes were protective in the MDD
group—CGAG and CGTG, with respective P¼ 0.003 and
P¼ 0.020. These P-values did not remain statistically
significant after correction for multiple testing. ATT-risk
haplotype from block nr 7 (rs4831140, rs6787168 and
rs16824996) differed statistically significantly in the MDD
group (P¼ 0.042), but this P-value also did not survive the
correction. Other haplotypes did not significantly differ between
the patient and control groups (data not shown). On a closer
analysis of frequencies of minor alleles of haplotype block nr 5,
the risk haplotype TATA appeared more frequently than
protective haplotype CGAG in the MDD group (41 vs 17%)
as compared with their respective control group (31 vs 23%;
w2-test Po0.001). The same trend was observed in PD group-
risk haplotype TATA was more frequent than protective
haplotype CGAG (38 vs 20%) as compared with their
respective control group (31 vs 24%; w2-test P¼ 0.003).
Discussion
Our findings indicate that the LSAMP gene is possibly related
to MDD and PD. We detected statistically significant allelic
associations between four LSAMP SNPs and MDD. Two
SNPs out of these four contributed to the increased risk
(rs1461131 and rs4831089) and two were protective
(rs16824691 and rs9874470). Only two risk SNPs above
were related to PD. Haplotype block nr 5 was formed from
the forenamed SNPs giving three statistically significant
haplotypes in the MDD group: TATA being risk haplotype
and CGAG and CGTG being a protective haplotype. Risk
haplotype TATA was also statistically significant in the PD
group. Closer analysis of minor alleles of haploblock 5
indicated that the proportion of risk SNPs was higher in
patient groups as compared with control groups. Sub-analysis
by gender suggested that LSAMP gene polymorphisms are
evidently more related to males than to females, as no
statistically significant association was detected in the female
PD group. Plausibly, LSAMP gene polymorphisms contribute
to shared genetic factors of MDD and PD, as associations
were detected across both groups.
The LSAMP gene and protein show high similarity between
the humans and rodents, suggesting strong phylogenetic
conservation of the protein structure and associated func-
tional properties.10 The LSAMP gene has two alternative first
exons (1a and 1b) separated by a 1.5-Mb-long intron, which
give rise to two different mRNA transcripts.37 A preliminary
in situ RNA hybridization analysis has demonstrated sub-
stantially different expression patterns of Lsamp 1a and
1b transcripts in mouse brain, with the 1b predominantly
expressed in sensory nuclei of the brainstem, in the thalamus
and in sensory areas of the cortex (Philips et al., unpublished).
It has been suggested that large 50-introns contain regulatory
elements involved in silencing and spatial and temporal
patterns of gene expression.37 Interestingly, all associated
SNPs in our study reside in the first intron (1b) and may affect
regulation of gene expression. Two different Lsamp gene
knockout mouse lines have been created.33,38 Overlapping
between the phenotype of these lines is remarkable; both
knockout mice are vital and fertile with no gross abnormal-
ities.33 The first line, in which the second exon of Lsamp is
deleted, exhibits hyperactivity in novel situations, altered
synaptic transmission and impaired plasticity in the hippo-
campus, inducing deficits in spatial memory acquisition and
retention.38,39 The other line, in which the 1b exon of Lsamp is
deleted, exhibits slower swim velocity, hyperactivity in novel
situations, reduced anxiety, reduced aggressiveness and
decrease of barbering behavior in male mice; however, their
Table 2 Results of allelic association analysis


















1 rs16824996 50-Flanking region T/C 0.14 0.15 0.380 0.14 0.15 0.585
2 rs6787168 50-Flanking region T/C 0.33 0.37 0.081 0.36 0.37 0.623
3 rs4831140 50-Flanking region A/T 0.21 0.25 0.123 0.24 0.25 0.552
4 rs988803 Intron 1 T/A 0.24 0.24 0.887 0.23 0.25 0.586
5 rs7634137 Intron 1 T/C 0.16 0.18 0.167 0.15 0.18 0.277
6 rs1920191 Intron 1 G/A 0.28 0.29 0.618 0.28 0.30 0.595
7 rs1461131 Intron 1 G/A 0.44 0.36 o0.001* 0.43 0.37 0.033
8 rs16824691 Intron 1 T/A 0.19 0.26 0.004 0.23 0.26 0.210
9 rs4831089 Intron 1 G/A 0.43 0.33 o0.001* 0.41 0.34 0.018
10 rs9874470 Intron 1 T/C 0.26 0.36 o0.001* 0.31 0.36 0.059
11 rs2944425 Intron 3 C/T 0.41 0.41 0.794 0.41 0.41 0.796
12 rs9830559 Intron 3 T/C 0.41 0.40 0.765 0.41 0.40 0.798
13 rs10511350 Intron 3 G/C 0.10 0.11 0.541 0.13 0.11 0.310
14 rs6763835 Intron 4 C/T 0.40 0.39 0.803 0.39 0.39 0.921
15 rs4416377 Intron 4 T/C 0.21 0.21 0.866 0.21 0.21 0.974
16 rs2918213 Intron 6 C/T 0.32 0.33 0.629 0.33 0.33 0.981
17 rs2918215 Intron 6 G/A 0.09 0.11 0.362 0.10 0.11 0.570
18 rs2918217 Intron 6 G/A 0.14 0.13 0.385 0.14 0.13 0.727
19 rs9822311 Intron 6 G/C 0.29 0.27 0.428 0.29 0.27 0.559
20 rs9821809 30-Flanking region G/A 0.21 0.22 0.694 0.19 0.22 0.244
21 rs2918239 30-Flanking region T/G 0.16 0.16 0.861 0.15 0.15 0.774
Abbreviations: MDD, major depressive disorder; Min allele, minor allele; PD, panic disorder.
P-value p0.05 bolded.
*P-value p0.05 after 10 000 permutations.
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spatial memory and learning curve were similar to that of
wild-type mice.33,40 Altogether, these results suggest that
altered expression of LSAMP leads to differences in neuronal
connectivity, causing only subtle disturbance in signaling but
measurable changes in functional output.38 Furthermore, the
lack of LSAMP protein seems to result in an inability to adapt
or react to novel environments or stressful environmental
manipulations.40 Thus, a properly regulated level of LSAMP
expression appears to be required for normal neuronal
functioning. A former study has demonstrated that intraven-
tricular administration of anti-LSAMP to postnatal rats
resulted in aberrant growth of the mossy fiber projection in
the hippocampus.9 However, more recent study showed no
major alterations in the brain organization and gross
connectivity in the Lsamp-deficient mouse.38 To our knowl-
edge, the direct impact of LSAMPoverexpression on neuronal
Figure 1 Haplotype blocks of the limbic system-associated membrane protein (LSAMP ) gene in major depressive disorder (MDD) group.
Table 3 Haplotypes of block 5 in MDD group







T A T A 0.36 0.41 0.31 o0.001*
T G T G 0.29 0.29 0.29 0.932
C G A G 0.20 0.17 0.23 0.003
C G T G 0.09 0.07 0.10 0.020
T G T A 0.02 0.02 0.02 0.403
T A T G 0.02 0.02 0.02 0.961
C G A A 0.02 0.01 0.02 0.423
Abbreviation: MDD, major depressive disorder
P-value p0.05 bolded.
*P-value p0.05 after 10 000 permutations.
Table 4 Haplotypes of block 5 in PD group







T A T A 0.34 0.38 0.31 0.020
T G T G 0.28 0.27 0.28 0.757
C G A G 0.22 0.20 0.24 0.124
C G T G 0.09 0.08 0.10 0.330
T G T A 0.02 0.01 0.02 0.248
T A T G 0.02 0.02 0.02 0.858
C G A A 0.02 0.02 0.02 0.845
Abbreviation: PD, panic disorder.
P-value p0.05 bolded.
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circuitry has not yet been investigated, but the animal studies
indicate a relationship between heightened expression of
LSAMP and anxiety. Our speculation is that risk SNPs in 1b
intron may cause an increased expression of the LSAMP
gene, which results in elevated anxiety and a negative effect.
Several limitations of our study should be recognized. The
sample sizes were rather small, especially the PDmale group.
The patients in both MDD and PD groups had comorbid
diagnoses. Not all associations survived correction for multi-
ple testing, and we cannot exclude false-positive results. Also,
our study lacks functional analysis of the associated SNPs.
Therefore, replication association studies in independent
samples and imaging genetic studies are needed to confirm
and extend our findings. Further functional research is
required to determine the relevance of LSAMP function to
the molecular mechanisms of psychiatric disorders.
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